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Abstract
Introduction: The goal of this study is to analyze the potential immunosuppressive properties of mesenchymal
stem cells (MSC) on T cell proliferation and in collagen-induced arthritis (CIA). An additional aim is to investigate
the role of interferon-g (IFN-g) in these processes.
Methods: MSC were isolated from bone marrow of DBA/1 wild type and IFN-g receptor knock-out (IFN-gR KO)
mice and expanded in vitro. Proliferation of anti-CD3-stimulated CD4+ T cells in the presence or absence of MSC
was evaluated by thymidine incorporation. CIA was induced in DBA/1 mice and animals were treated with MSC by
intravenous or intraperitoneal injections of wild type or IFN-gR KO MSC.
Results: Purity of enriched MSC cultures was evaluated by flow cytometry and their ability to differentiate into
osteoblasts and adipocytes. In vitro, wild type MSC dose-dependently suppressed anti-CD3-induced T cell
proliferation whereas IFN-gR KO MSC had a significantly lower inhibitory potential. A role for inducible nitric oxide
(iNOS), programmed death ligand-1 (PD-L1) and prostaglandin E2 (PGE2), but not indoleamine 2,3-dioxigenase
(IDO), in the T cell inhibition was demonstrated. In vivo, neither wild type nor IFN-gR KO MSC were able to reduce
the severity of CIA or the humoral or cellular immune response toward collagen type II.
Conclusions: Whereas MSC inhibit anti-CD3-induced proliferation of T cells in vitro, an effect partially mediated by
IFN-g, MSC do not influence in vivo T cell proliferation nor the disease course of CIA. Thus there is a clear
discrepancy between the in vitro and in vivo effects of MSC on T cell proliferation and CIA.
Introduction
Bone marrow-derived mesenchymal stem cells (MSCs)
are multipotent progenitor cells that can differentiate
into cells of the mesenchymal lineage like bone, fat, and
cartilage [1]. Due to these characteristics, they have
been postulated as attractive candidates for cell-based
tissue repair (for instance, to restore cartilage defects)
[2,3]. MSCs have therefore been suggested as an innova-
tive therapeutic tool for rheumatic diseases [4]. Besides
their regenerative potential, MSCs have immunomodula-
tory properties by interaction with immunocompetent
cells (reviewed in [5,6]). MSCs inhibit proliferation of T
cells in response to mitogenic stimuli [7] and anti-CD3
and anti-CD28 antibody stimulation [8,9]. Multiple
mechanisms have been proposed by which MSCs inhibit
T-cell responses. Prostaglandin E2 (PGE2), nitric oxide
(NO), indoleamine 2,3-dioxigenase (IDO), and pro-
grammed death ligand-1 (PD-L1) (also known as B7-
H1) are among the most often postulated molecules to
be involved in inhibition of T-cell proliferation by MSCs
[10-12]. Besides the involvement of soluble factors,
induction of T-cell anergy has emerged as an alternative
mechanism of T-cell inhibition [13]. To suppress T-cell
responses, MSCs first need to be activated by cytokines
produced by activated T cells [14,15], like interferon-
gamma (IFN-g). Although IFN-g has traditionally been
considered a pro-inflammatory cytokine, evidence that
IFN-g can also fulfill potent immunomodulatory proper-
ties is accumulating [16]. Stimulation with IFN-g can
induce MSCs to inhibit T-cell proliferation [12,15]. In
vivo data on MSC-mediated immunosuppression, how-
ever, are less conclusive. When graft-versus-host disease
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is induced in mice, treatment with MSCs does not
always result in amelioration of the disease [17-19]. T
cell-mediated autoimmune diseases like experimental
autoimmune encephalomyelitis and experimental auto-
immune enteropathy demonstrated an amelioration of
symptoms after treatment with MSCs [20-22]. Treat-
ment of collagen-induced arthritis (CIA), an animal
model for rheumatoid arthritis, with MSCs has also
been investigated. While three studies report ameliora-
tion of arthritic symptoms [23-25], others were unable
to see beneficial effects of MSC treatment on the devel-
opment of CIA [26,27]. In patients with rheumatoid
arthritis, MSCs were able to suppress collagen-specific
T-cell responses in vitro [28]. To strengthen the experi-
mental background for future therapy with MSCs, we
addressed the effect of MSCs on in vitro and in vivo T-
cell proliferation and on CIA in this study. In addition,
we investigated the role of IFN-g by using MSCs isolated
from IFN-g receptor knockout (IFN-gR KO) mice.
Materials and methods
Isolation and expansion of mesenchymal stem cells
DBA/1 mice were bred in the Animal Centre of the Uni-
versity of Leuven. Bone marrow from 4- to 6-week-old
DBA/1 and DBA/1 IFN-gR KO mice was flushed out of
the femurs and tibias by using phosphate-buffered saline
(PBS) supplemented with 2% fetal calf serum (FCS)
(Gibco, now part of Invitrogen Corporation, Carlsbad,
CA, USA). Cells were washed once with PBS 2% FCS and
plated at a concentration of 0.6 to 0.8 × 106 cells/cm2 in
Murine Mesencult medium (StemCell Technologies,
Vancouver, BC, Canada) supplemented with 100 U/ml
penicillin (Continental Pharma, Brussels, Belgium) and
100 μg/ml streptomycin (Continental Pharma). Cells
were cultured in a humidified atmosphere with 5% CO2
at 37°C. Half of the medium was replaced after 2 days
and thereafter twice a week for 3 weeks. When the colo-
nies that had formed reached confluence, adherent cells
were collected following a 5-minute incubation at 37°C
with 0.05% trypsin/ethylenediaminetetraacetic acid
(EDTA) (Gibco) and replated. MSCs of C57BL/6 origin
were kindly provided by Darwin J Prockop and Catherine
Verfaillie.
Flow cytometric characterization and differentiation of
mesenchymal stem cells
MSCs were harvested by incubation with trypsin/EDTA
and counted. MSCs were washed with PBS 2% FCS,
stained with the indicated antibodies for 30 minutes and
washed twice with PBS 2% FCS. For the biotin-conju-
gated antibody, a second staining step with streptavidin
conjugated to fluorescein isothiocyanate (FITC) was per-
formed. Finally, the cells were fixed with 0.37% formal-
dehyde in PBS. The following antibodies were purchased
from eBioscience (San Diego, CA, USA): Sca-1-FITC
(stem cell antigen-1 [Ly-6A/E]), CD34-FITC, MHC-I-
FITC, CD31-phycoerythrin (platelet endothelial cell
adhesion molecule [PCAM]-PE), CD73-PE (ecto-5’-
nuleotidase), MHC-II-PE, CD11b-PE, CD105-biotin
(endoglin), and CD45-phycoerythrin-cyanine-5 (PE-Cy5).
Flow cytometric analysis was performed on a FACSCali-
bur flow cytometer with CellQuest® software (BD Bios-
ciences, San Jose, CA, USA). For differentiation, MSCs
were plated in six-well plates and grown to confluence.
Osteogenesis and adipogenesis were induced as
described previously [29] and [30], respectively).
Anti-CD3-induced cell proliferation
CD4+ T cells and accessory cells (ACs) were isolated
from DBA/1 mice and cultured in RPMI medium as
described previously [31]. CD4+ T cells (5 × 104 per
well) were cultured in flat-bottomed 96-well plates with
mitomycin-c-treated (Sigma-Aldrich, St. Louis, MO,
USA) ACs (5 × 104 per well) and 3 μg/ml anti-CD3
antibody in the presence or absence of the indicated
numbers of mitomycin-c-treated MSCs. The cultures
were incubated for 72 hours at 37°C in 5% CO2 and
pulsed for the last 16 hours with 1 μCi of [3H]TdR and
harvested. The suppressive capacity of the MSCs is
represented by the percentage inhibition. Alternatively,
CD4+ T cells were labeled with carboxyfluorescein suc-
cinimidyl ester (CFSE) (Invitrogen Corporation, Carls-
bad, CA, USA) before culture to analyze cell
proliferation. T cells were resuspended in PBS 5% FCS
at a concentration of 1 to 2 × 106 cells/ml and incu-
bated with CFSE (final concentration of 50 μM) for 5
minutes at room temperature. Cells were washed three
times with PBS 5% FCS and resuspended in culture
medium at the indicated concentrations. For restoration
of T-cell proliferation, co-cultures were grown in the
presence of 200 μM 1-methyl-DL-tryptophan (Sigma-
Aldrich), 10 μM indomethacin (Sigma-Aldrich), or 10
μM GW274150 (Alexis Biochemicals, Farmingdale, NY,
USA).
Measurement of in vivo T-cell proliferation
In vivo T-cell proliferation was measured using the
Click-iT™ EdU Flow Cytometry Assay Kit (Invitrogen
Corporation). EdU (5-ethynyl-2’-deoxyuridine) is a
nucleoside analog to thymidine and is incorporated into
DNA during active DNA synthesis. One milligram of
EdU in 100 μl of PBS was injected intraperitoneally into
each mouse. After 4 hours, mice were sacrificed and
lymph nodes (axillary, inguinal, and mesenteric) and
spleens were harvested. Single-cell suspensions were
obtained as described above and were incubated for 15
minutes with the Fc receptor-blocking antibodies anti-
CD16 and anti-CD32 (CD16/CD32; Miltenyi Biotec,
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Bergisch Gladbach, Germany). Cells were washed with
PBS 1% bovine serum albumin (BSA) and incubated
with anti-CD4-FITC and anti-CD8-Per-CP antibodies
(eBioscience) for 30 minutes and then washed twice
with PBS 1% BSA followed by detection of incorporated
EdU in accordance with the manufacturer’s instructions.
Flow cytometric analysis was performed on a FACSCali-
bur flow cytometer with CellQuest® software.
Quantitative polymerase chain reaction
RNA extraction, cDNA synthesis, and real-time quantita-
tive polymerase chain reaction (PCR) for inducible nitric
oxide (iNOS), IDO, cyclo-oxigenase-2 (COX-2), and PD-
L1 (assay ID Mm00440485_m1, Mm00492586_m1,
Mm01307334_g1, and Mm00452054_m1, respectively;
Applied Biosystems, Foster City, CA, USA) were per-
formed as described previously [32].
Bio-Plex protein array system
Expression of cytokines (that is, interleukin-2 [IL-2], IL-
5, IL-6, IL-10, IL-17, and IFN-g) was determined by the
Bio-Plex 200 system, Bio-Plex mouse Cytokine 8-plex
assay, Bio-Plex mouse IL-6 assay, and Bio-Plex mouse
IL-17 assay (Bio-Rad Laboratories, Inc., Hercules, CA,
USA).
Collagen-induced arthritis induction and treatment
protocols
Experiments were performed in 8- to 12-week-old DBA/
1 mice. CIA was induced and clinically assessed as
described previously [33]. To test the effect of MSCs on
the disease course of CIA, mice were injected intrave-
nously or intraperitoneally with 1 × 106 MSCs in 100 μl
of sterile PBS at the indicated time points. Controls
received injections of an equal volume of PBS at the
same time points. All animal experiments were approved
by the local ethics committee (University of Leuven).
Measurement of anti-CII antibodies and delayed-type
hypersensitivity to CII
Blood samples were taken from the orbital sinus or by
heart puncture and were allowed to clot at room tem-
perature for 1 hour and at 4°C overnight. Individual sera
were tested for antibodies directed to chicken collagen
type II (CII) by enzyme-linked immunosorbent assay as
described earlier [31]. For evaluation of delayed-type
hypersensitivity (DTH) reactivity, CII/complete Freund’s
adjuvant (CFA)-immunized mice were subcutaneously
injected with 20 μg of CII/20 μl of PBS in the right ear
and with 20 μl of PBS in the left ear. DTH response was
calculated as the percentage swelling (the difference
between the increase of thickness of the right ear and
the left ear, divided by the thickness of the left ear, mul-
tiplied by 100).
Statistical analysis
Data are expressed as the mean (standard error of the
mean). Differences were analyzed by the Mann-Whitney
U test. A P value of not more than 0.05 was considered
significant.
Results
Generation of mesenchymal stem cells and phenotypical
analysis
MSCs were generated from bone marrow cells of DBA/1
wild-type and DBA/1 IFN-gR KO mice. After removal of
nonadherent cells, colonies were formed. These colonies
were morphologically heterogeneous until passage 5 or
6, consisting of both round and fibroblast-like cells. Het-
erogeneity was also evident from phenotypical analysis
of the cell cultures by flow cytometry. During the first 2
to 4 passages, cell cultures consisted predominantly of
CD11b+ and CD45+ hematopoietic cells (Figure 1a, b).
The original population of bone marrow cells was
enriched with MSCs during subsequent passages. From
passage 7 onward, a homogenous CD11b-CD45-Sca-1+
population of MSCs was reached for both wild-type and
IFN-gR KO cultures (passages 7 and 12 are depicted in
Figure 1a, b). Additional flow cytometric analysis
demonstrated that the MSC cultures from passage 7
were positive for CD73, CD80, and MHC-I and negative
for CD31, CD34, CD86, CD90, CD105, and MHC-II
(WT MSCs, Figure 1c; IFN-gR KO MSCs, Figure 1d).
The isolated mesenchymal stem cells differentiate into
osteogenic and adipogenic lineages
To assess the multipotentiality of the cultured mouse
MSCs, cells were subjected to in vitro osteogenic and
adipogenic differentiation assays. In osteogenic medium,
the MSCs of both wild-type and IFN-gR KO origin
formed aggregates and showed enhanced calcium
deposition as revealed by Alizarin Red stain (Figure 1e,
middle and lower left panels) as compared with control
cultures grown in medium without additives. By cultur-
ing the MSCs in adipogenic medium, only MSCs from
DBA/1 IFN-gR KO mice showed some adipogenic differ-
entiation (Figure 1e, lower right panel), whereas MSCs
of DBA/1 wild-type origin showed no adipogenic differ-
entiation (Figure 1c, middle right panel).
Mesenchymal stem cells suppress anti-CD3-induced T-cell
proliferation in vitro by a mechanism involving interferon-
gamma, inducible nitric oxide, and cyclo-oxigenase-2
To investigate the immunosuppressive potential of
MSCs in vitro, we tested their effect on the anti-CD3-
induced proliferation of CD4+ T cells. T cells were sti-
mulated in vitro with anti-CD3 antibody in the absence
or presence of MSCs and their proliferation was ana-
lyzed by thymidine incorporation. MSCs of wild-type
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origin dose-dependently inhibited anti-CD3-induced T-
cell proliferation (Figure 2a). IFN-gR KO MSCs had a
significantly lower inhibitory capacity (Figure 2a). Prolif-
eration was also measured by analysis of CFSE-labeled
CD4+ T cells. Similarly, a lower suppressive capacity of
IFN-gR KO MSCs as compared with wild-type MSCs
was seen (Figure 2b).
These data demonstrate the importance of IFN-g sig-
naling in MSCs to suppress T-cell proliferation. To
investigate which molecules are involved in the suppres-
sion of proliferation, quantitative PCR was performed
on IL-17- and IFN-g-stimulated wild-type MSCs. These
stimuli were chosen based on their upregulated expres-
sion in CD4+ T cells by stimulation with anti-CD3 anti-
bodies (Figure 3a) and because these cytokines have
been shown to synergistically induce the expression of
iNOS [34] and IDO [35] in fibroblasts. The expression
of iNOS, IDO, PD-L1, and COX-2, molecules involved
in inhibition of T-cell proliferation and known to be
induced by IFN-g in MSCs [11], was analyzed. Unstimu-
lated MSCs expressed no or low levels of these
inhibitory factors (Figure 3b-d). Upon stimulation with
IL-17 or IFN-g alone, expression of PD-L1 (Figure 3b),
iNOS (Figure 3c), and COX-2 (Figure 3d) was upregu-
lated mildly. However, when IL-17 and IFN-g were
added simultaneously, expression levels of PD-L1,
iNOS, and COX-2 (Figure 3b-d) were synergistically
upregulated. IDO mRNA could not be detected in
unstimulated or stimulated MSCs (data not shown).
These data indicate that IFN-g acts synergistically with
IL-17 to upregulate expression of PD-L1, iNOS, and
COX-2 in MSCs, making these molecules candidate
mediators of T-cell inhibition. The involvement of
iNOS and COX-2 in inhibition of T-cell proliferation
was demonstrated by the addition of inhibitors of these
enzymes - GW274150 and indomethacin [8,36], respec-
tively - to the co-cultures. The addition of these inhibi-
tors resulted in the abrogation of the inhibition of T-
cell proliferation by wild-type MSCs (Figure 3e). The
addition of the IDO inhibitor 1-methyl-DL-tryptophan
(1-MT) did not affect the inhibition conferred by MSCs
(Figure 3e).
Figure 1 Phenotype and differentiation potential of mesenchymal stem cells (MSCs). Bone marrow cells of DBA/1 wild-type and
interferon-gamma receptor knockout (IFN-gR KO) mice were cultured in Murine Mesencult medium and phenotyped. (a-d) MSCs were
incubated with the indicated antibodies and analyzed by flow cytometry. Grey histograms show stained cells, and black lines represent cells
incubated with isotype controls. Wild-type MSCs were analyzed at passages 3, 4, and 7 (a) and IFN-gR KO MSCs were analyzed at passages 2 and
12 (b) for expression of CD11b, CD45, and Sca-1. Likewise, other phenotypic markers were analyzed on wild-type (c) and IFN-gR KO (d) MSCs. (e)
MSCs were cultured to confluency in Murine Mesencult medium and then transferred to adipogenic or osteogenic differentiation medium for 21
days, followed by Oil Red O or Alizarin Red staining, respectively (original magnification × 10). The inset in the lower right panel represents an
enlargement of the adipocyte indicated by the arrow.
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Mesenchymal stem cell treatment has no effect on the
development of collagen-induced arthritis
To test the possible involvement of MSCs in CIA, DBA/1
mice were immunized with CII in CFA on day 0 and
injected intravenously with wild-type or IFN-gR KO
MSCs at different time points (Table 1). In a first experi-
ment, day -1 was chosen for treatment with MSCs
because experiments previously performed in our labora-
tory demonstrated that one single injection of CD4
+CD25+ regulatory T (Treg) cells at day -1 significantly
inhibited CIA [37]. In fact, in this experiment, a group of
mice that received Treg cells were included. Injection of
either wild-type or IFN-gR KO MSCs at day -1 did not
affect the severity or incidence of arthritis, whereas injec-
tion of Treg cells did reduce the severity of CIA. In two
subsequent experiments, we considered treating the mice
at later time points, when inflammation was already
ongoing. Thus, MSCs were administered at day 16
(experiment 2 in Table 1) or at day 16 and 23 post-
immunization (experiment 3 in Table 1 and Figure 4).
Treatment of the mice did not influence the disease
severity or the incidence of arthritis development
(Table 1 and Figure 4a, b) as compared with PBS-treated
control animals. To verify whether the failure of MSCs to
affect clinical scores of arthritis was also reflected in cel-
lular and humoral autoimmune responses, DTH and
total anti-CII IgG were analyzed. Anti-CII IgG titers were
similar between MSC-treated and PBS-treated mice
(Figure 4c). In addition, DTH responses, as evident from
the percentage of swelling upon challenge with CII, were
not different between MSC-treated and control animals
(Figure 4d). T-cell proliferation was also measured in
these mice by injection of 10 μg of anti-CD3 antibody.
The results revealed no differences in CD4+ and CD8+
T-cell proliferation in spleens and lymph nodes when
arthritic mice were injected intravenously with wild-type
or IFN-gR KO MSCs (Figure 4e). However, since T-cell
activation is a combination of proliferation and cytokine
production, the sera of anti-CD3-injected and MSC-trea-
ted mice were analyzed for cytokines. The serum of mice
was pooled per group and analyzed for the T-cell cyto-
kines IL-2, IL-5, IL-6, IL-10, and IFN-g. The injection of
anti-CD3 antibody caused a profound increase in cyto-
kine levels in the sera of these mice. Treatment with
wild-type or IFN-gR KO MSCs, however, did not result
in a decrease of IL-2, IL-5, and IL-10 but slightly
decreased the levels of IL-6 and IFN-g (data not shown).
Since in recently reported studies MSCs that success-
fully affected CIA were injected intraperitoneally [23,24],
we performed an additional experiment in which wild-
type or IFN-gR KO MSCs were administered intraperi-
toneally. Similarly to the intravenous administration,
Figure 2 Mesenchymal stem cells (MSCs) inhibit the anti-CD3-
induced proliferation of CD4+ T cells in vitro. (a) CD4+ T cells
(5 × 104 cells) and accessory cells (5 × 104 cells) were incubated
with 3 μg/ml anti-CD3 antibody and the indicated numbers of
mitomycin c-treated wild-type or interferon-gamma receptor
knockout (IFN-gR KO) MSCs for 72 hours and pulsed for the last 16
hours with 1 μCi of [3H]TdR. The percentage inhibition (100 ×
[(radioactivity in cultures without MSCs – radioactivity in cultures
with MSCs)/radioactivity in cultures without MSCs]) by increasing
numbers of MSCs is shown. Each result represents the mean of four
cultures ± standard error of the mean (SEM). Results are
representative of two independent experiments. * P < 0.05 for
comparison with wild-type MSCs (Mann-Whitney U test). (b)
Carboxyfluorescein succinimidyl ester (CFSE)-labeled CD4+ T cells
(5 × 104 cells) and accessory cells (5 × 104 cells) were incubated
with 3 μg/ml anti-CD3 antibody and the indicated numbers of
mitomycin c-treated wild-type or IFN-gR KO MSCs for 72 hours. The
proliferation of CD4+ T cells was analyzed by detection of CFSE
dilution by flow cytometry. The percentage inhibition (100 ×
[(percentage of proliferating CD4+ cells not treated with MSCs –
percentage of proliferating CD4+ cells treated with MSCs)/
percentage of proliferating CD4+ cells not treated with MSCs]) by
increasing numbers of MSCs is shown. Each result represents the
mean of three cultures ± SEM. Results are representative of two
independent experiments. * P < 0.05 for comparison with wild-type
MSCs (Mann-Whitney U test).
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Figure 3 Mesenchymal stem cells (MSCs) inhibit the proliferation of CD4+ T cells in vitro by induction of nitric oxide and
prostaglandin E2 (PGE2). (a) CD4
+ T cells, in the presence of accessory cells, were stimulated with 3 μg/ml anti-CD3 for 48 hours. Interleukin-17
(IL-17) and interferon-gamma (IFN-g) levels in the supernatant of these cultures were analyzed by Bio-Plex protein array system. Bars represent
averages of three values ± standard error of the mean. (b-d) Wild-type MSCs were stimulated with IL-17 (20 ng/mL) or IFN-g (100 U/mL) or both
for 48 hours. cDNA samples were prepared and subjected to quantitative polymerase chain reaction analysis. The relative quantity of target
mRNA levels was normalized for 18S RNA. Relative levels of programmed death ligand-1 (PD-L1) (b), inducible nitric oxide (iNOS) (c), and cyclo-
oxigenase-2 (COX-2) (d) are shown. Bars represent averages of two values. ND, not detectable. (e) CD4+ T cells (5 × 104 cells) and accessory cells
(5 × 104 cells) were incubated with 3 μg/ml anti-CD3 antibody and the indicated number of mitomycin c-treated wild-type MSCs for 72 hours
and pulsed for the last 16 hours with 1 μCi of [3H]TdR. Co-cultures were grown in the absence (control) or presence of 200 μM 1-methyl-DL-
tryptophan, 10 μM indomethacin, or 10 μM GW274150. The percentage inhibition (100 × [(radioactivity in cultures without MSCs – radioactivity
in cultures with MSCs)/radioactivity in cultures without MSCs]) by increasing numbers of MSCs is shown.
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intraperitoneal treatment with MSCs did not influence
the disease severity or incidence of arthritis compared
with PBS-treated control mice (experiment 4 in Table
1). Here again, anti-CII IgG antibody levels were not dif-
ferent compared with controls (data not shown). The
MSCs used in reference [23] were, however, of C57BL/6
origin. To exclude the possibility that the difference in
treatment outcome depends on the mouse strain from
which the MSCs are isolated, we performed an addi-
tional experiment in which MSCs of C57BL/6 origin
were intraperitoneally injected. Again, there was no dif-
ference in cumulative incidence and mean arthritic
score between the C57BL/6 MSC-treated and control-
treated mice (experiment 5 in Table 1). The results of
all experiments are summarized in Table 1.
Discussion
Besides their inherent ability to differentiate into
mesenchymal cell lineages [1] and their potential to
repair damaged tissue [2,3], MSCs have been shown to
exert immunosuppressive properties on T cells. For this
reason, studies to test the use of MSCs for treatment of
several T cell-mediated inflammatory diseases have been
conducted. In CIA, the effect of MSCs on the disease
severity was not clear-cut [23-27]. Therefore, in the pre-
sent study, we assessed the effect of MSCs on in vitro
and in vivo T-cell proliferation as well as on CIA. By
using MSCs of both IFN-gR KO and wild-type origin,
we also addressed the role of IFN-g in the immunomo-
dulatory properties of MSCs.
The obtained MSCs demonstrated a phenotype that
matches the generally accepted phenotype for murine
MSCs, being positive for CD73 and Sca-1 and negative
for CD11b, CD31, CD34, CD45, and CD90 [38]. Differ-
entiation toward osteocytes could be demonstrated in
wild-type and IFN-gR KO MSCs and was equally potent
in the two cell types. The differentiation of MSCs
toward adipocytes was much less pronounced. A possi-
ble explanation for this observation can be the DBA/1
origin of the MSCs. Indeed, it has been demonstrated
that DBA/1 MSCs formed osteocytes very potently but
differentiation into adipocytes was much more difficult
in this mouse strain compared with other strains [30].
Co-culturing anti-CD3-stimulated T cells and MSCs
clearly resulted in an inhibition of T-cell proliferation in
an IFN-g-dependent way. This observation is in agree-
ment with other reports emphasizing the role of IFN-g
in MSC-mediated immunosuppression [11,12,15,39].
When T-cell proliferation was analyzed by radioactive
thymidine incorporation, a higher suppression of T-cell
proliferation could be achieved compared with analysis
by CFSE dilution. A possible explanation for this differ-
ence might be the time frame during which proliferation
was analyzed since MSCs need IFN-g from activated T
cells to suppress immune responses. CFSE is present
from the start of the culture, whereas [3H]TdR is added
only during the last 16 hours of cell culture. Thus, the
CFSE-based method measures all T-cell proliferation,
whereas the [3H]TdR method measures only late T-cell
proliferation, when the inhibition by MSCs is ongoing.
Irrespective of the method that is used for measurement
Table 1 Cumulative incidence and mean scores of arthritis in mice treated with wild-type or IFN-gR KO DBA/1 MSCs or
with C57BL/6 MSCsa
Experiment Routeb Administration timec Treatmentd Cumulative incidencee,
fraction (percentage)
Score of arthritis,
mean ± SEMe, f
1 i.v. Day -1 Control 4/8 (50%) 2.0 ± 0.9
Wild-type MSCs 1/2 (50%) 1.5 ± 1.5
IFN-gR KO MSCs 3/7 (43%) 1.6 ± 1.0
Treg cells 2/8 (25%) 0.4 ± 0.3
2 i.v. Day 16 Control 4/10 (40%) 1.3 ± 0.7
Wild-type MSCs 6/8 (75%) 2.1 ± 0.6
IFN-gR KO MSCs 4/10 (40%) 0.8 ± 0.4
3 i.v. Days 16 and 23 Control 5/10 (50%) 3.0 ± 1.4
Wild-type MSCs 5/9 (56%) 2.5 ± 0.9
IFN-gR KO MSCs 5/10 (50%) 2.0 ± 0.8
4 i.p. Days 16, 23, and 30 Control 7/8 (88%) 5.1 ± 1.5
Wild-type MSCs 6/7 (86%) 5.3 ± 1.2
IFN-gR KO MSCs 8/9 (89%) 4.6 ± 1.6
5 i.p. Days 16, 23, and 30 Control 7/11 (64%) 1.3 ± 0.5
C57BL/6 MSCs 8/11 (73%) 2.7 ± 1.2
aMice were immunized with collagen type II in complete Freund’s adjuvant on day 0 and were treatedb either intravenously (i.v.) or intraperitoneally (i.p.) on the
indicated time pointsc with wild-type mesenchymal stem cells (MSCs), interferon-gamma receptor knockout (IFN-gR KO) MSCs, C57BL/6 MSCs, regulatory T (Treg)
cells, or phosphate-buffered saline (control group)d. eArthritic incidence and score of arthritis in all groups at day 35. fArthritic scores were not significantly
different between control treatment and treatment with wild-type or IFN-gR KO DBA/1 MSCs or C57BL/6 MSCs or with Treg cells. SEM, standard error of the mean.
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of T-cell proliferation, IFN-gR KO MSCs display a
defect in their potential to inhibit T-cell proliferation.
We identified a possible role for NO, PD-L1, and
PGE2 but not IDO in the inhibition of T-cell prolifera-
tion by MSCs. Several independent reports identified
NO as being one of the major mediators of T-cell sup-
pression by MSCs [10,15,39,40], whereas controversy
about the involvement of IDO still exists [8,11,41,42].
The same holds true for PD-L1 and PGE2, with reports
supporting [11,12] and refuting [8,11] a role for these
two T-cell inhibitors in T-cell proliferation inhibition. In
addition, we could demonstrate that IL-17, in synergy
with IFN-g, can induce the expression of iNOS, COX-2,
and PD-L1 in MSCs. Thus, IL-17 and IFN-g from
activated T cells can induce MSCs to suppress ongoing
T-cell responses in vitro.
Treatment with MSCs did not affect the disease
course of CIA. The pathogenesis of CIA, an animal
model of human rheumatoid arthritis, depends on both
CII-specific T cells and antibody responses against CII
[43,44]. Both of these specific immune responses against
CII remained unaffected upon transfer of MSCs. In five
experiments, MSCs administered intravenously or intra-
peritoneally did not affect the development of arthritis
(Table 1). A possible explanation for the discrepancy
between the in vitro and in vivo settings might be that
the intravenously injected MSCs do not reach the spleen
and lymph nodes and are therefore unable to inhibit the
Figure 4 Treatment with mesenchymal stem cells (MSCs) of wild-type or interferon-gamma receptor knockout (IFN-gR KO) origin does
not influence the development of collagen-induced arthritis in DBA/1 mice. Mice were immunized on day 0 with collagen type II (CII) in
complete Freund’s adjuvant and injected intravenously with MSCs on day 16 and day 23. The mean arthritic score (a) and the cumulative
incidence of arthritis (b) in DBA/1 mice treated with phosphate-buffered saline (PBS), wild-type MSCs, or IFN-gR KO MSCs are shown. Error bars
represent standard error of the mean (SEM). (c) On day 46, sera of individual mice were analyzed for total anti-CII IgG. Histograms represent
averages ± SEM. (d) Forty-two days after immunization, five mice in each group were challenged with 10 μg of CII in the right ear and vehicle
in the left ear. Delayed-type hypersensitivity responses were measured as the percentage of swelling (100 × [(thickness of the right ear –
thickness of the left ear)/thickness of the left ear]) at the indicated times. Histograms indicate averages ± SEM. (e) On day 19 after immunization
with CII in complete Freund’s adjuvant, DBA/1 wild-type mice were injected intravenously with 1 × 106 wild-type MSCs, IFN-gR KO MSCs, or PBS,
followed by an administration of 10 μg of anti-CD3 antibody on day 20. On day 21, in vivo T-cell proliferation was measured by detection of 5-
ethynyl-2’ -deoxyuridine (EdU) in the T-cell populations in the spleen and lymph nodes by fluorescence-activated cell sorting analysis. The
percentages of EdU-positive cells in the CD4+ and CD8+ populations in the spleen and lymph nodes are shown. Histograms represent averages
of four mice ± SEM.
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T-cell proliferation and CIA. In rats, radioactively
labeled MSCs distribute mainly to the lungs and liver
when intravenously administered [45,46]. Only small
amounts of radioactivity could be detected in the spleen.
Moreover, evidence exists that MSCs lose their homing
ability to bone marrow after 48 hours of culture [47].
Since the MSCs used in this report were cultured for
several weeks, cells may have lost their ability for hom-
ing to lymphoid organs. This homing ability can be
improved by genetic manipulation of MSCs before
transfer, as evident from a recent study reporting
improved homing of MSCs to bone marrow in mice
after overexpression of the chemokine receptor CXCR4
[48].
These results are in contrast to three reports [23-25]
demonstrating that the administration of MSCs has a
beneficial effect on disease severity in CIA. Other
reports, however, support our data. Choi and colleagues
[27] have shown that MSCs administered intravenously
do not suppress the development of arthritis, unless
they were transduced with IL-10, indicating that MSCs
as such are not immunosuppressive in CIA. Similarly, in
another study, it is reported that intravenous adminis-
tration of the immortalized MSC cell line C3H10T1/2
to immunized mice had no effect on the development of
CIA [26]. The treatment protocols and results of these
studies are summarized in Table 2. Thus, overall, the
results obtained with MSC treatment for CIA are incon-
clusive. This is in contrast to transfer of Treg cells for
the treatment of CIA. When mice are injected with 1 ×
106 Treg cells either before immunization or after disease
onset, the severity of arthritis is dramatically diminished
(Table 1 and [37,49]).
Conclusions
Our data demonstrate that murine bone marrow-derived
MSCs potently inhibit in vitro T-cell proliferation in an
IFN-g-dependent mechanism that involves NO and
PGE2. These in vitro data, however, could not be extra-
polated to an in vivo situation. Neither in vivo anti-
CD3-induced T-cell proliferation nor the development
of CIA was affected by MSC treatment. Thus, although
MSCs provide promising tools for the treatment of sev-
eral autoimmune diseases, prudence is called for in
extrapolating in vitro and animal data to the human
situation.
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